IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
Zhen Ning Wee(Agency for Science, Technology and Research), Qiang Yu(Agency for Science, Technology and Research)
Cited by 170
Related Papers
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
|Nature Communications|2021|115
HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer
|Proceedings of the National Academy of Sciences|2016|90
RASAL2 activates RAC1 to promote triple-negative breast cancer progression
|Journal of Clinical Investigation|2014|86
Apoptosis Signal-regulating Kinase 1 Is a Direct Target of E2F1 and Contributes to Histone Deacetylase Inhibitorinduced Apoptosis through Positive Feedback Regulation of E2F1 Apoptotic Activity
|Journal of Biological Chemistry|2006|63
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
|Nature Communications|2020|54